Does Pneumococcal Vaccination Have an Effect on Hospital Costs?

Nurdan Şimşek Veske, Özgür Uslu, Özlem Oruç, Sedat Altın, Enver Yalnız, Zuhal Karakurt, Erkut Bolat, Seval Kul, Oğuz Kılınç, Abdullah Sayıner
Author Information
  1. Nurdan Şimşek Veske: Department of Chest Disease, University of Health Sciences Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey.
  2. Özgür Uslu: Department of Chest Disease, University of Health Sciences İzmir Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, İzmir, Turkey.
  3. Özlem Oruç: Department of Chest Disease, University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey.
  4. Sedat Altın: Department of Chest Disease, University of Health Sciences Yedikule Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey.
  5. Enver Yalnız: Department of Chest Disease, University of Health Sciences İzmir Suat Seren Chest Diseases and Thoracic Surgery Training and Research Hospital, İzmir, Turkey.
  6. Zuhal Karakurt: Department of Chest Disease, University of Health Sciences Süreyyapaşa Chest Diseases and Thoracic Surgery Training and Research Hospital, İstanbul, Turkey.
  7. Erkut Bolat: Department of Bioistatistics and Medical Informatics, İstanbul University Faculty of Medicine, İstanbul, Turkey.
  8. Seval Kul: Department of Biostatistics and Medical Informatics, Gaziantep University School of Medicine, Gaziantep, Turkey.
  9. Oğuz Kılınç: Department of Pulmonary, Dokuz Eylül University Faculty of Medicine, İzmir, Turkey.
  10. Abdullah Sayıner: Department of Pulmonary Diseases, Ege University, Faculty of Medicine, Izmir, Turkey.

Abstract

OBJECTIVE: It is known that inpatient hospital costs are much higher than outpatient services. It was aimed to investigate the effect of pneumococcal vaccination on hospitalizations.
MATERIAL AND METHODS: The direct hospitalization costs, length of stay, and factors of the vaccinated and unvaccinated patients in the same hospital during the 12-month follow-up of the patients who received pneumococcal vaccine between November 15, 2018, and November 15, 2020, in 3 chest diseases and thoracic surgery training and research hospitals were analyzed by obtaining Hospital Information Management System records. Data were collected with Statistical Package for the Social Sciences version 23 program (IBM Corp.; Armonk, NY, USA) , and statistical evaluation was made.
RESULTS: The mean age of 800 hospitalized patients, of whom 400 were unvaccinated and 400 were vaccinated, was 68.48 ± 11.97. There was no significant difference in the mean age of vaccinated and unvaccinated patients (P > .05). Five hundred sixty-six patients (70.8%) were aged 65 and over. Two hundred eighty (51.2%) of men were vaccinated and 120 (47.2%) of women were vaccinated, and there was no significant difference (P > .05). The mean hospital stay of these patients was 11.01 days, and those in the vaccinated group had an average mean hospital stay of 9.11 days and those in the unvaccinated group had a mean hospital stay less than 12.91 days (P < .001). Total 1-year hospitalization costs were $501.653.53 and the cost per person was calculated as $627.07. The cost per capita for the vaccinated group was $550.52, which was lower than the average cost of the unvaccinated group ($703.62) (P < .05). When comparing the status of being vaccinated, comorbidity, mortality, mean length of stay, chronic obstructive pulmonary disease, and heart disease were found to be statistically significant (P < .05).
CONCLUSION: In our study, it was revealed that vaccination of patients hospitalized in chest disease hospitals with the pneumococcal vaccine reduced the average length of hospital stay by 41.7% and the cost of hospitalization by 27.8%.

References

  1. Tuberk Toraks. 2020 Sep;68(3):305-320 [PMID: 33295729]
  2. Eur Respir J. 2001 Jul;18(1):151-6 [PMID: 11510787]
  3. Am J Med. 2004 Aug 2;117 Suppl 3A:39S-50S [PMID: 15360096]
  4. Clin Microbiol Infect. 2012 Oct;18 Suppl 5:7-14 [PMID: 22882668]
  5. Thorax. 1996 Oct;51(10):1010-6 [PMID: 8977602]
  6. Intern Med. 2001 Aug;40(8):703-7 [PMID: 11518106]
  7. Clin Respir J. 2014 Jan;8(1):93-9 [PMID: 23889911]
  8. Eur Respir J. 2006 Aug;28(2):346-51 [PMID: 16611653]
  9. Pharmacoeconomics. 2004;22(7):413-20 [PMID: 15137880]
  10. Hum Vaccin Immunother. 2017 Jul 3;13(7):1673-1680 [PMID: 28281915]
  11. Tuberk Toraks. 2007;55(2):191-212 [PMID: 17602349]
  12. Minerva Anestesiol. 2011 Feb;77(2):196-211 [PMID: 21242952]
  13. Int J Chron Obstruct Pulmon Dis. 2016 Mar 02;11:455-65 [PMID: 27042038]
  14. Chest. 2005 Oct;128(4):2238-46 [PMID: 16236880]
  15. BMC Health Serv Res. 2012 Oct 31;12:379 [PMID: 23113880]
  16. Bull World Health Organ. 2008 Feb;86(2):140-6 [PMID: 18297169]
  17. Am J Med. 2005 Jul;118 Suppl 7A:29S-38S [PMID: 15993675]
  18. Patient. 2013;6(2):125-34 [PMID: 23549929]
  19. Expert Rev Vaccines. 2016;15(3):279-93 [PMID: 26651847]
  20. Am J Med. 2003 Oct 1;115(5):343-51 [PMID: 14553868]
  21. N Engl J Med. 2008 Nov 27;359(22):2355-65 [PMID: 19038881]

Word Cloud

Created with Highcharts 10.0.0vaccinatedpatientshospitalstaymeanunvaccinatedP05groupcostcostspneumococcalhospitalizationlength11significantdaysaverage<diseasevaccinationvaccineNovember15chesthospitalsHospitalagehospitalized400difference>hundred8%2%perOBJECTIVE:knowninpatientmuchhigheroutpatientservicesaimedinvestigateeffecthospitalizationsMATERIALANDMETHODS:directfactors12-monthfollow-upreceived201820203diseasesthoracicsurgerytrainingresearchanalyzedobtainingInformationManagementSystemrecordsDatacollectedStatisticalPackageSocialSciencesversion23programIBMCorpArmonkNYUSAstatisticalevaluationmadeRESULTS:8006848±97Fivesixty-six70aged65Twoeighty51men12047women019less1291001Total1-year$50165353personcalculated$62707capita$55052lower$70362comparingstatuscomorbiditymortalitychronicobstructivepulmonaryheartfoundstatisticallyCONCLUSION:studyrevealedreduced417%27PneumococcalVaccinationEffectCosts?

Similar Articles

Cited By